Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin and Pioglitazone in Type 2 Diabetes
NCT07053319Phase 1Recruiting
- Sponsor
- UT Health San Antonio
- Start
- May 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of empagliflozin and pioglitazone in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by UT Health San Antonio. Primary endpoint: Endogenous Glucose Production at 300 minutes. Started May 2026; status: recruiting.
02
Drugs
empagliflozinpioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07053319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07053319.